Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001371 · ClinicalTrials.gov registry record
A Pilot Study of Topical Antiflammin-2 for Psoriasis
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 24
- Enrollment target
NCT00001371: Completed study, sponsored by National Cancer Institute (NCI).
NCT00001371 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001371 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2 (PLA2) inhibitor, in the treatment of chronic plaque psoriasis. Antiflammin-2 in an ointment base, or the vehicle alone will each be applied four times per day to a single plaque in a randomized, double-blinded fashion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1993-12 |
| Est. Completion | 2000-12 |
What the finished NCT00001371 record still lists
NCT00001371 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00001371 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001371 about?
NCT00001371 is a clinical study titled "A Pilot Study of Topical Antiflammin-2 for Psoriasis". This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2 (PLA2) inhibitor, in the treatment of chronic plaque psoriasis. Antiflammin-2 in an ointment base, or the vehicle alone will each be applied four times per day to a single plaque in a randomized, double-blinde...
What is the current status of trial NCT00001371?
This trial is currently completed. The enrollment target is 24 participants. The study started on 1993-12. Estimated completion is 2000-12.
Who is sponsoring clinical trial NCT00001371?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia